Valuation Metrics: A Closer Look
UTI AMC’s price-to-earnings (P/E) ratio currently stands at 26.00, a figure that positions it favourably against many of its peers in the capital markets sector. This P/E is notably lower than the likes of Aditya AMC (31.42), Star Health Insurance (54.13), and Anand Rathi Wealth (74.95), all of which are classified as very expensive. The company’s price-to-book value (P/BV) is 2.82, which, while not the lowest in the sector, remains reasonable given the firm’s return on equity (ROE) of 10.84% and return on capital employed (ROCE) of 18.01%.
Enterprise value to EBITDA (EV/EBITDA) is another critical metric where UTI AMC shows strength at 15.35, considerably lower than Anand Rathi Wealth’s 61.28 and Star Health Insurance’s 40.77. This suggests that the company is trading at a more moderate multiple relative to its earnings before interest, taxes, depreciation, and amortisation, signalling better value for investors seeking exposure to the capital markets sector.
Comparative Valuation and Peer Analysis
When benchmarked against its peers, UTI AMC’s valuation grade has improved from very attractive to attractive, a subtle upgrade that reflects a narrowing gap between price and intrinsic value. While many competitors remain in the very expensive category, UTI AMC’s valuation metrics suggest a more balanced risk-reward profile. For instance, Angel One, classified as expensive, has a P/E of 31.65 but a lower EV/EBITDA of 11.2, indicating a mixed valuation picture across the sector.
Other peers such as Nuvama Wealth and Go Digit General continue to trade at elevated multiples, with P/E ratios of 28.28 and 52.75 respectively, and EV/EBITDA ratios that are significantly higher than UTI AMC’s. This relative valuation advantage could attract investors looking for capital markets exposure without the premium pricing seen in other names.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
Price Performance and Market Context
UTI AMC’s current market price is ₹987.85, up from the previous close of ₹974.55, with a 52-week high of ₹1,494.95 and a low of ₹897.75. The stock’s recent price action shows resilience, with a one-week return of 3.18% outperforming the Sensex’s decline of 1.62%. Over the one-month period, UTI AMC gained 2.24%, again surpassing the Sensex’s negative 1.98% return.
However, year-to-date (YTD) returns remain negative at -12.5%, slightly worse than the Sensex’s -10.8%. Over longer horizons, the stock has delivered robust gains, with a three-year return of 50.9% compared to the Sensex’s 22.79%, though the five-year return of 39.2% trails the Sensex’s 54.62%. These mixed returns highlight the stock’s cyclical nature and sensitivity to broader market conditions.
Financial Health and Dividend Yield
UTI AMC’s dividend yield stands at a healthy 4.84%, offering a steady income stream to investors amid valuation shifts. The company’s EV to capital employed ratio of 2.95 and EV to sales of 6.62 further underline its operational efficiency and capital utilisation. These metrics, combined with a PEG ratio of zero, suggest that the company’s earnings growth expectations are either stable or not yet fully priced in by the market.
Such fundamentals support the recent upgrade in valuation grade, indicating that the stock’s price now better reflects its earnings potential and capital efficiency compared to previous periods.
Risks and Considerations
Despite the improved valuation attractiveness, UTI AMC carries a Mojo Score of 38.0 and a Mojo Grade of Sell, downgraded from Hold on 20 Apr 2026. This rating reflects concerns over certain quality parameters or market risks that may temper investor enthusiasm. The company’s small-cap market capitalisation also implies higher volatility and liquidity risks compared to larger peers.
Investors should weigh these factors alongside valuation improvements, considering the broader capital markets environment and sector-specific headwinds that could impact future performance.
Why settle for UTI Asset Management Company Ltd? SwitchER evaluates this Capital Markets small-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Conclusion: Valuation Upgrade Reflects Renewed Investor Interest
UTI Asset Management Company Ltd’s shift from a very attractive to an attractive valuation grade signals a positive change in market perception, driven by improved price-to-earnings and enterprise value multiples relative to peers. While the stock’s Mojo Grade remains a Sell, the valuation metrics suggest that the price is becoming more reasonable for investors seeking exposure to the capital markets sector.
Its dividend yield of 4.84%, solid ROCE of 18.01%, and ROE of 10.84% provide additional support for the stock’s fundamental appeal. However, investors should remain cautious given the company’s small-cap status and recent downgrade in quality rating. The stock’s mixed return profile relative to the Sensex further emphasises the need for a balanced approach.
Overall, UTI AMC presents a more attractive valuation entry point than many of its expensive peers, making it a candidate for consideration in portfolios focused on capital markets exposure, provided investors are comfortable with the associated risks.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
